A Phase 2 interventional study of Topical SM04554 solution and Topical SM04554 solution in Androgenetic Alopecia, sponsored by Biosplice Therapeutics, Inc.. Completed at 24 sites in United States. Open to male participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Biosplice Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 217 studies in Alopecia with a site in United States — 43 open to participants now, 63 under way, 6 of them phase 3. Alopecia · United States.
Among the 217 studies in Alopecia with a site in United States, this one is the 19th largest by enrollment of the 204 interventional ones that give a count, is one of 6 that started in 2014, is one of 48 in phase 2, and was the 48th registered.
512 studies on the registry are indexed under Alopecia; 127 are open to participants now.
Browse Alopecia studies →43 of the 217 studies in Alopecia with a site in United States are open now. Recruiting first, the newest first:
Pelage Pharmaceuticals, Inc. · Sites in United States
Ages 18–65 · Women only
Pelage Pharmaceuticals, Inc. · Sites in United States, Canada
Ages 18–55 · Men only
Johns Hopkins University · Sites in United States
Ages 18–80
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+
University of Miami · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 75 Alopecia studies recruiting now, 24 (32%) set no upper age limit and 47 (63%) stop at 75 or younger; 10 take children under 18; 24 take healthy volunteers.
This study: 18 Years to 55 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
217 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 38 · Phase 2 58 · Phase 3 17 · Phase 4 9
First in 2000; this study’s year is marked. 6 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 302 is above the median of 50 across 431 interventional studies indexed under Alopecia.
Median enrollment 40 across the 204 interventional studies, 204 across the 12 observational. Of the 127 that completed or were terminated, 52 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
124 of 217 have an industry lead sponsor. The 10 most frequent:
Biosplice Therapeutics, Inc. is the lead sponsor of 22 studies on the registry; none are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 12 (67%) have results posted.
Biosplice Therapeutics, Inc. has 3 studies filed under Alopecia — fewer than ten, so there is no comparison to draw.
28 of the studies in Alopecia with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06972264Phase 3Veradermics, Inc.Safety and Efficacy of VDPHL01 in Males With AGA | 2026-12 |
| NCT07146022Phase 3Veradermics, Inc.Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA) | 2027-06 |
| NCT04207931Wake Forest University Health SciencesTreatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study | 2026-11 |
| NCT05416333Wake Forest University Health SciencesAzelaic Acid as a Novel Treatment for Central Centrifugal Cicatricial Alopecia (CCCA) | 2026-11 |
| NCT07588243CynosureLutronicA Clinical Study to Evaluate the Efficacy and Safety of Ultra in Promoting Hair Regrowth | 2026-12 |
Add all 28 to your calendar (.ics) → With an account.
Among the 217 studies in Alopecia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to characterize the safety, tolerability, and efficacy of topical SM04554 solution (0.15% and 0.25%) applied to the scalp of male subjects with Androgenetic Alopecia (AGA).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Topical SM04554 0.15% solution, applied once a day for 90 days
Drug: Topical SM04554 solution
Topical SM04554 0.25% solution, applied once a day for 90 days
Drug: Topical SM04554 solution
Topical vehicle solution, applied once a day for 90 days
Drug: Topical vehicle solution
Study medication application will be performed by the individual subject at approximately the same time each day.
Study medication application will be performed by the individual subject at approximately the same time each day.
Vehicle solution application will be performed by the individual subject at approximately the same time each day.
Change From Baseline in Non-vellus Hair Count
Change from baseline in non-vellus hair count over time. Non-vellus hair count was determined by macrophotography. Standardized macrophotography color photographs of the treatment area were taken on Visit Day 0 (pre-treatment), as well as on Visit Days 45 and 90, and 135. A circular area of the subject's hair 1.9 cm in diameter was clipped to approximately 1 mm in length prior to performing the macrophotography. On Visit Day 0, a scalp tattoo approximately 1 mm in size and located in the center of the target area of hair was applied to anchor the macrophotography. Photos were uploaded from sites to the vendor where blinded assessment of the macrophotography took place.
Time frame: Day 45, Day 90, and Day 135
Change in Subject Assessment of Hair Growth and Quality
Change in Men's Hair Growth Questionnaire (MHGQ) over time as compared to Baseline. The MHGQ is a subject-completed assessment that asks the subject to evaluate his hair growth and quality since the start of the study.
Time frame: Day 45, Day 90, and Day 135
Change in Hair Growth as Assessed by the Investigator
Change in hair growth over time as compared to Baseline, as assessed by the investigator, using a 7-point scale from -3 (greatly decreased) to +3 (greatly increased). Responses were analyzed using logistic regression modeling improvement vs no change/worsening of hair status at each visit.
Time frame: Day 45, Day 90, and Day 135
Impact of AGA on Quality of Life
Change from baseline in subject responses to the Kingsley Alopecia Profile (KAP) questionnaire over time. The KAP is a validated, patient-reported outcome that quantitatively measure the impact androgenetic alopecia on the subject's quality of life. Each of the 38 KAP 5-category Likert-scaled questions was scored +2 'Strongly Agree' to -2 'Strongly Disagree.' The KAP score was summed across all 38 questions for a score ranging from +76 to -76, with higher scores indicating an increasing negative impact on quality of life. Change from baseline was calculated as visit - baseline such that negative values reflecting improving quality of life.
Time frame: Day 45, Day 90, and Day 135
Change From Baseline in Total Sum of Hair Width
Non-vellus hair width was determined by macrophotography. Standardized macrophotography color photographs of the treatment area were taken on Visit Day 0 (pre-treatment), as well as on Visit Days 45 and 90, and 135. A circular area of the subject's hair 1.9 cm in diameter was clipped to approximately 1 mm in length prior to performing the macrophotography. On Visit Day 0, a scalp tattoo approximately 1 mm in size and located in the center of the target area of hair was applied to anchor the macrophotography. Photos were uploaded from sites to the vendor where blinded assessment of the macrophotography took place. While the protocol and SAP listed this outcome as hair density, the actual outcome analyzed was the total sum of non-vellus hair width in microns within the target area provided by macrophotography.
Time frame: Day 45, Day 90, and Day 135
| Milestone | SM04554 0.15% | SM04554 0.25% | Vehicle |
|---|---|---|---|
| Started | 102 | 102 | 98 |
| Completed | 74 | 77 | 76 |
| Not completed | 28 | 25 | 22 |
| Withdrew: Adverse event | 11 | 13 | 12 |
| Withdrew: Lost to follow-up | 4 | 4 | 1 |
| Withdrew: Protocol violation | 10 | 3 | 3 |
| Withdrew: Withdrawal by subject | 2 | 5 | 6 |
| Withdrew: Medication dispensing error | 1 | 0 | 0 |
Change from baseline in non-vellus hair count over time. Non-vellus hair count was determined by macrophotography. Standardized macrophotography color photographs of the treatment area were taken on Visit Day 0 (pre-treatment), as well as on Visit Days 45 and 90, and 135. A circular area of the subject's hair 1.9 cm in diameter was clipped to approximately 1 mm in length prior to performing the macrophotography. On Visit Day 0, a scalp tattoo approximately 1 mm in size and located in the center of the target area of hair was applied to anchor the macrophotography. Photos were uploaded from sites to the vendor where blinded assessment of the macrophotography took place.
| Non-vellus hair count | SM04554 0.15% | SM04554 0.25% | Vehicle |
|---|---|---|---|
| Day 45 | 4.6 ± 16.97 | 2.6 ± 14.35 | 5.7 ± 13.27 |
| Day 90 (Primary efficacy, treatment completion, time point) | 4.2 ± 17.88 | 3.2 ± 15.66 | 6.2 ± 14.75 |
| Day 135 | 7.9 ± 17.95 | 3.3 ± 15.78 | 4.2 ± 18.77 |
Change in Men's Hair Growth Questionnaire (MHGQ) over time as compared to Baseline. The MHGQ is a subject-completed assessment that asks the subject to evaluate his hair growth and quality since the start of the study.
| Participants | SM04554 0.15% | SM04554 0.25% | Vehicle |
|---|---|---|---|
| 1. Bald spot getting smaller - Day 45 — Worsening | 55 | 39 | 38 |
| 1. Bald spot getting smaller - Day 45 — No Change | 24 | 37 | 32 |
| 1. Bald spot getting smaller - Day 45 — Improvement | 13 | 21 | 20 |
| 1. Bald spot getting smaller - Day 90 — Worsening | 51 | 44 | 40 |
| 1. Bald spot getting smaller - Day 90 — No Change | 14 | 20 | 23 |
| 1. Bald spot getting smaller - Day 90 — Improvement | 13 | 18 | 17 |
| 1. Bald spot getting smaller - Day 135 — Worsening | 51 | 47 | 44 |
| 1. Bald spot getting smaller - Day 135 — No Change | 11 | 18 | 19 |
| 1. Bald spot getting smaller - Day 135 — Improvement | 14 | 15 | 12 |
| 2. Appearance of hair - Day 45 — Worsening | 10 | 10 | 8 |
| 2. Appearance of hair - Day 45 — No Change | 55 | 55 | 52 |
| 2. Appearance of hair - Day 45 — Improvement | 27 | 32 | 30 |
| 2. Appearance of hair - Day 90 — Worsening | 9 | 13 | 5 |
| 2. Appearance of hair - Day 90 — No Change | 52 | 44 | 51 |
| 2. Appearance of hair - Day 90 — Improvement | 17 | 25 | 24 |
| 2. Appearance of hair - Day 135 — Worsening | 18 | 11 | 13 |
| 2. Appearance of hair - Day 135 — No Change | 41 | 45 | 43 |
| 2. Appearance of hair - Day 135 — Improvement | 17 | 24 | 19 |
| 3. Growth of hair - Day 45 — Worsening | 8 | 10 | 5 |
| 3. Growth of hair - Day 45 — No Change | 56 | 50 | 48 |
| 3. Growth of hair - Day 45 — Improvement | 28 | 37 | 37 |
| 3. Growth of hair - Day 90 — Worsening | 10 | 10 | 6 |
| 3. Growth of hair - Day 90 — No Change | 47 | 42 | 43 |
| 3. Growth of hair - Day 90 — Improvement | 21 | 30 | 31 |
| 3. Growth of hair - Day 135 — Worsening | 13 | 10 | 11 |
| 3. Growth of hair - Day 135 — No Change | 44 | 41 | 35 |
| 3. Growth of hair - Day 135 — Improvement | 19 | 29 | 29 |
| 4. Slowing hair loss - Day 45 — Worsening | 63 | 60 | 52 |
| 4. Slowing hair loss - Day 45 — No Change | 0 | 0 | 0 |
| 4. Slowing hair loss - Day 45 — Improvement | 29 | 37 | 38 |
| 4. Slowing hair loss - Day 90 — Worsening | 51 | 48 | 43 |
| 4. Slowing hair loss - Day 90 — No Change | 0 | 0 | 0 |
| 4. Slowing hair loss - Day 90 — Improvement | 27 | 34 | 37 |
| 4. Slowing hair loss - Day 135 — Worsening | 60 | 51 | 51 |
| 4. Slowing hair loss - Day 135 — No Change | 0 | 0 | 0 |
| 4. Slowing hair loss - Day 135 — Improvement | 16 | 29 | 24 |
| 5a. Satisfaction with frontal hairline - Day 45 — Worsening | 28 | 22 | 21 |
| 5a. Satisfaction with frontal hairline - Day 45 — No Change | 51 | 61 | 45 |
| 5a. Satisfaction with frontal hairline - Day 45 — Improvement | 13 | 14 | 24 |
| 5a. Satisfaction with frontal hairline - Day 90 — Worsening | 31 | 26 | 29 |
| 5a. Satisfaction with frontal hairline - Day 90 — No Change | 39 | 36 | 35 |
| 5a. Satisfaction with frontal hairline - Day 90 — Improvement | 8 | 19 | 15 |
| 5a. Satisfaction with frontal hairline - Day 135 — Worsening | 35 | 26 | 22 |
| 5a. Satisfaction with frontal hairline - Day 135 — No Change | 28 | 41 | 37 |
| 5a. Satisfaction with frontal hairline - Day 135 — Improvement | 13 | 13 | 16 |
| 5b. Satisfaction with hair on top - Day 45 — Worsening | 37 | 27 | 31 |
| 5b. Satisfaction with hair on top - Day 45 — No Change | 41 | 50 | 42 |
| 5b. Satisfaction with hair on top - Day 45 — Improvement | 14 | 20 | 16 |
| 5b. Satisfaction with hair on top - Day 90 — Worsening | 36 | 39 | 33 |
| 5b. Satisfaction with hair on top - Day 90 — No Change | 34 | 30 | 37 |
| 5b. Satisfaction with hair on top - Day 90 — Improvement | 8 | 12 | 8 |
| 5b. Satisfaction with hair on top - Day 135 — Worsening | 37 | 41 | 36 |
| 5b. Satisfaction with hair on top - Day 135 — No Change | 28 | 28 | 27 |
| 5b. Satisfaction with hair on top - Day 135 — Improvement | 11 | 11 | 11 |
| 5c. Satisfaction with hair overall - Day 45 — Worsening | 32 | 26 | 30 |
| 5c. Satisfaction with hair overall - Day 45 — No Change | 46 | 53 | 40 |
| 5c. Satisfaction with hair overall - Day 45 — Improvement | 14 | 18 | 19 |
| 5c. Satisfaction with hair overall - Day 90 — Worsening | 32 | 34 | 29 |
| 5c. Satisfaction with hair overall - Day 90 — No Change | 34 | 31 | 36 |
| 5c. Satisfaction with hair overall - Day 90 — Improvement | 12 | 15 | 12 |
| 5c. Satisfaction with hair overall - Day 135 — Worsening | 32 | 29 | 29 |
| 5c. Satisfaction with hair overall - Day 135 — No Change | 31 | 37 | 36 |
| 5c. Satisfaction with hair overall - Day 135 — Improvement | 13 | 14 | 9 |
Change in hair growth over time as compared to Baseline, as assessed by the investigator, using a 7-point scale from -3 (greatly decreased) to +3 (greatly increased). Responses were analyzed using logistic regression modeling improvement vs no change/worsening of hair status at each visit.
| Participants | SM04554 0.15% | SM04554 0.25% | Vehicle |
|---|---|---|---|
| Day 45 — Worsening | 3 | 4 | 6 |
| Day 45 — No Change | 58 | 61 | 58 |
| Day 45 — Improvement | 30 | 31 | 26 |
| Day 90 — Worsening | 6 | 5 | 3 |
| Day 90 — No Change | 46 | 52 | 49 |
| Day 90 — Improvement | 26 | 25 | 28 |
| Day 135 — Worsening | 10 | 7 | 12 |
| Day 135 — No Change | 43 | 49 | 39 |
| Day 135 — Improvement | 23 | 24 | 25 |
Change from baseline in subject responses to the Kingsley Alopecia Profile (KAP) questionnaire over time. The KAP is a validated, patient-reported outcome that quantitatively measure the impact androgenetic alopecia on the subject's quality of life. Each of the 38 KAP 5-category Likert-scaled questions was scored +2 'Strongly Agree' to -2 'Strongly Disagree.' The KAP score was summed across all 38 questions for a score ranging from +76 to -76, with higher scores indicating an increasing negative impact on quality of life. Change from baseline was calculated as visit - baseline such that negative values reflecting improving quality of life.
| score on a scale | SM04554 0.15% | SM04554 0.25% | Vehicle |
|---|---|---|---|
| Day 45 | -2.0 ± 12.39 | 0.7 ± 15.15 | -0.6 ± 11.01 |
| Day 90 | -3.2 ± 14.89 | -2.1 ± 14.18 | -1.3 ± 11.97 |
| Day 135 | -3.7 ± 12.39 | -0.9 ± 16.32 | -1.1 ± 13.64 |
Non-vellus hair width was determined by macrophotography. Standardized macrophotography color photographs of the treatment area were taken on Visit Day 0 (pre-treatment), as well as on Visit Days 45 and 90, and 135. A circular area of the subject's hair 1.9 cm in diameter was clipped to approximately 1 mm in length prior to performing the macrophotography. On Visit Day 0, a scalp tattoo approximately 1 mm in size and located in the center of the target area of hair was applied to anchor the macrophotography. Photos were uploaded from sites to the vendor where blinded assessment of the macrophotography took place. While the protocol and SAP listed this outcome as hair density, the actual outcome analyzed was the total sum of non-vellus hair width in microns within the target area provided by macrophotography.
| microns | SM04554 0.15% | SM04554 0.25% | Vehicle |
|---|---|---|---|
| Day 45 | 105.7 ± 847.77 | 110.6 ± 738.23 | 227.0 ± 754.95 |
| Day 90 | 98.3 ± 966.59 | 41.3 ± 788.52 | 245.7 ± 832.60 |
| Day 135 | 235.4 ± 904.89 | 31.2 ± 814.93 | 43.3 ± 970.88 |
Collected over AEs were assessed at each study visit from the start of study medication application on Day 1 through Day 135 (End of Study) which was 45 days after last application of study medication.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SM04554 0.15% | 0/102 (0%) | 0/102 (0%) | 45/102 (44.1%) |
| SM04554 0.25% | 0/102 (0%) | 0/102 (0%) | 46/102 (45.1%) |
| Vehicle | 0/98 (0%) | 1/98 (1%) | 47/98 (48%) |
| Event | SM04554 0.15% | SM04554 0.25% | Vehicle |
|---|---|---|---|
| Small intestinal obstructionGastrointestinal disorders | 0/102 | 0/102 | 1/98 |
| Event | SM04554 0.15% | SM04554 0.25% | Vehicle |
|---|---|---|---|
| Application site erythemaGeneral disorders and administration site conditions | 5/102 | 7/102 | 5/98 |
| Application site pruritusGeneral disorders and administration site conditions | 6/102 | 4/102 | 6/98 |
| Application site paraesthesiaGeneral disorders and administration site conditions | 6/102 | 3/102 | 6/98 |
| Skin exfoliationSkin and subcutaneous tissue disorders | 2/102 | 3/102 | 6/98 |
| PruritusSkin and subcutaneous tissue disorders | 1/102 | 4/102 | 1/98 |
| CoughRespiratory, thoracic and mediastinal disorders | 4/102 | 0/102 | 1/98 |
| HeadacheNervous system disorders | 1/102 | 1/102 | 3/98 |
| SinusitisInfections and infestations | 0/102 | 1/102 | 3/98 |
| ErythemaSkin and subcutaneous tissue disorders | 0/102 | 0/102 | 3/98 |
| NauseaGastrointestinal disorders | 1/102 | 3/102 | 2/98 |
All subjects who received at least one dose of study treatment
| Age, Continuous(years) | SM04554 0.15% | SM04554 0.25% | Vehicle | Total |
|---|---|---|---|---|
| Mean | 44.2 ± 8.21 | 44.7 ± 8.83 | 45.0 ± 8.60 | 44.6 ± 8.53 |
| Sex: Female, Male(Participants) | SM04554 0.15% | SM04554 0.25% | Vehicle | Total |
|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 |
| Male | 102 | 102 | 98 | 302 |
| Ethnicity (NIH/OMB)(Participants) | SM04554 0.15% | SM04554 0.25% | Vehicle | Total |
|---|---|---|---|---|
| Hispanic or Latino | 14 | 22 | 18 | 54 |
| Not Hispanic or Latino | 88 | 80 | 80 | 248 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | SM04554 0.15% | SM04554 0.25% | Vehicle | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 1 |
| Asian | 1 | 1 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 1 | 2 | 0 | 3 |
| Black or African American | 10 | 10 | 6 | 26 |
| White | 89 | 88 | 90 | 267 |
| More than one race | 1 | 1 | 1 | 3 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | SM04554 0.15% | SM04554 0.25% | Vehicle | Total |
|---|---|---|---|---|
| United States | 102 | 102 | 98 | 302 |
| Weight [kg](kg) | SM04554 0.15% | SM04554 0.25% | Vehicle | Total |
|---|---|---|---|---|
| Mean | 95.90 ± 17.334 | 94.15 ± 18.320 | 92.50 ± 19.535 | 94.21 ± 18.394 |
| Height [cm](cm) | SM04554 0.15% | SM04554 0.25% | Vehicle | Total |
|---|---|---|---|---|
| Mean | 178.64 ± 7.802 | 177.58 ± 7.731 | 177.46 ± 7.246 | 177.90 ± 7.595 |
| Norwood-Hamilton Classification Score(Participants) | SM04554 0.15% | SM04554 0.25% | Vehicle | Total |
|---|---|---|---|---|
| 4 | 29 | 36 | 35 | 100 |
| 5 | 9 | 14 | 17 | 40 |
| 5A | 18 | 11 | 22 | 51 |
| 5V | 26 | 22 | 14 | 62 |
| 6 | 20 | 19 | 10 | 49 |
Ran from Nov 2014 to primary completion in Nov 2015, 12 months.
Results were first posted in Oct 2026, 10 years 11 months after primary completion. A results delay was requested in Jul 2018.
Of 25 industry-sponsored phase 2 interventional studies under Alopecia, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 12 months is close to that.
Counting every sponsor, half of 42 studies reached it within 13 months; a quarter within 9 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dalosirvat
Biosplice Therapeutics, Inc. →